{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:20Z","timestamp":1740134840928,"version":"3.37.3"},"reference-count":9,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,29]]},"DOI":"10.1182\/blood.2020009964","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T12:32:52Z","timestamp":1619699572000},"page":"2277-2278","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["DLBCL outcomes: much ventured, much GAINED"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6938","authenticated-orcid":false,"given":"Andrew","family":"Davies","sequence":"first","affiliation":[{"name":"Southampton General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"17","key":"2021042912322504200_B1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"31","key":"2021042912322504200_B2","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021042912322504200_B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2021042912322504200_B4","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"2021042912322504200_B5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood.2019003277","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial","volume":"135","author":"Sch\u00f6der","year":"2020","journal-title":"Blood"},{"issue":"20","key":"2021042912322504200_B6","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9806","key":"2021042912322504200_B7","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"R\u00e9cher","year":"2011","journal-title":"Lancet"},{"key":"2021042912322504200_B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial [published correction appears in Eur J Cancer. 2020;136:207-208]","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"2021042912322504200_B9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/17\/2277\/1805893\/bloodbld2020009964c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/17\/2277\/1805893\/bloodbld2020009964c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T17:57:57Z","timestamp":1619978277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/17\/2277\/475803\/DLBCL-outcomes-much-ventured-much-GAINED"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":9,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,4,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009964","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,4,29]]}}}